<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01809327</url>
  </required_header>
  <id_info>
    <org_study_id>CR100034</org_study_id>
    <secondary_id>28431754DIA3011</secondary_id>
    <secondary_id>2011-000400-17</secondary_id>
    <nct_id>NCT01809327</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise</brief_title>
  <official_title>A Randomized, Double-Blind, 5-Arm, Parallel-Group, 26-Week, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in Combination With Metformin as Initial Combination Therapy in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Research &amp; Development, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effectiveness of the co-administration of
      canagliflozin and metformin extended release (XR) compared with canagliflozin alone, and
      metformin XR alone in patients with type 2 diabetes mellitus with inadequate control despite
      treatment with diet and exercise. The safety and tolerability of canagliflozin will also be
      assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a randomized (the study medication is assigned by chance), double-blind
      (neither physician nor participant knows the identity of the assigned treatment),
      active-controlled (one of the treatments is an established effective treatment for type 2
      diabetes mellitus), parallel-group (each group of participants will be treated at the same
      time), 5-arm (groups), multicenter study. Approximately 1,200 participants will be randomly
      assigned to the 5 treatment arms in a 1:1:1:1:1 ratio for 26 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 4, 2013</start_date>
  <completion_date type="Actual">December 2, 2014</completion_date>
  <primary_completion_date type="Actual">December 2, 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The change in the value of glycated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) from baseline at Week 26 was compared between the different treatment groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Body Weight From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The percentage change in body weight from baseline to Week 26 was compared between the different treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Glycated Hemoglobin (HbAIc) Less Than 7 Percent at Week 26</measure>
    <time_frame>Week 26</time_frame>
    <description>The percentage of participants achieved HbAIc less than 7 percent at Week 26 was compared between the different treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Systolic Blood Pressure From Baseline at Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The change in systolic blood pressure from baseline at Week 26 was compared between the different treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Fasting High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The percentage change in Fasting High-Density Lipoprotein Cholesterol (HDL-C) from baseline to Week 26 was compared between the different treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Triglycerides From Baseline to Week 26</measure>
    <time_frame>Day 1 (Baseline) and Week 26</time_frame>
    <description>The percentage change in triglycerides from baseline to Week 26 was compared between the different treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment Emergent Adverse Events (AEs)</measure>
    <time_frame>Up to 30 weeks of last study drug administration</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1186</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one 100 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin 100 mg + Metformin XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Canagliflozin 300 mg + Metformin XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin 100 mg</intervention_name>
    <description>One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).</description>
    <arm_group_label>Canagliflozin 100 mg</arm_group_label>
    <arm_group_label>Canagliflozin 100 mg + Metformin XR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Canagliflozin 300 mg</intervention_name>
    <description>One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).</description>
    <arm_group_label>Canagliflozin 300 mg</arm_group_label>
    <arm_group_label>Canagliflozin 300 mg + Metformin XR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin XR</intervention_name>
    <description>One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.</description>
    <arm_group_label>Metformin XR</arm_group_label>
    <arm_group_label>Canagliflozin 100 mg + Metformin XR</arm_group_label>
    <arm_group_label>Canagliflozin 300 mg + Metformin XR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have type 2 diabetes mellitus with inadequate glycemic control on diet and
             exercise

          -  Not on antihyperglycemic agent therapy (at least 12 weeks before screening) and have a
             screening visit fingerstick glycated hemoglobin (HbA1c) of more than or equal to 7
             percent and less than or equal to 12.5 percent

          -  Have a screening visit HbA1c of more than or equal to 7.5 percent and less than or
             equal to 12 percent as determined by the central laboratory

          -  Must have a fasting plasma glucose of less than or equal to 300 mg/dL (16.7 mmol/L)
             prior to randomization

          -  Must have a fasting fingerstick glucose of greater than 120 mg/dL (6.7 mmol/L)
             performed at home or at the study center prior to randomization

        Exclusion Criteria:

          -  History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or
             beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy

          -  Fasting C-peptide less than 0.70 ng/mL (0.23 nmol/L) in participants for whom the
             investigator cannot reasonably exclude T1DM based upon clinical evaluation

          -  Repeated (2 or more over a 1 week period) fasting self-monitored blood glucose
             measurements more than 300 mg/dL (16.7 mmol/L) prior to randomization, despite
             reinforcement of diet and exercise counseling

          -  History of hereditary glucose-galactose malabsorption or primary renal glucosuria

          -  Has history of, or currently active, illness considered to be clinically significant
             by the Investigator or any other illness that the Investigator considers should
             exclude the patient from the study or that could interfere with the interpretation of
             the study results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Research &amp; Development, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Research &amp; Development, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Encinitas</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northridge</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Northglenn</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Opa-locka</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perry</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mandeville</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Picayune</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Seneca</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mooresville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mason</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yukon</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tualatin</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fleetwood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norristown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pearland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciudad Autonoma De Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cordoba</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mar Del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moron</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zarate</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Passo Fundo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kromeriz</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pardubice</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha 8</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Praha</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Unicov</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Balatonfured</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Szikszó</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zalaegerszeg</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goyang-Si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Celaya</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durango</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guadalajara</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Monterrey</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pachuca De Soto</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carolina</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trujillo Alto</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bacau</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oradea</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tg Mures</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Arkhangelsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barnaul</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelyabinsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Penza</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rostov-On-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Samara</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smolensk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St-Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syktyvkar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tyumen</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voronezh</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Malacky</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Presov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rimavska Sobota</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sahy</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trebisov</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halfway</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg N/A</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Soweto, Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Worcester</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherkasy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dnepropetrovsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ivano Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kharkov</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Odesa</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Poltava</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sumy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Zaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Czechia</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Puerto Rico</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Chile</country>
    <country>Colombia</country>
    <country>Czech Republic</country>
    <country>New Zealand</country>
    <country>Peru</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2013</study_first_submitted>
  <study_first_submitted_qc>March 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2013</study_first_posted>
  <results_first_submitted>December 1, 2015</results_first_submitted>
  <results_first_submitted_qc>December 1, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 6, 2016</results_first_posted>
  <last_update_submitted>June 12, 2017</last_update_submitted>
  <last_update_submitted_qc>June 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus, Type 2</keyword>
  <keyword>Diabetes Mellitus</keyword>
  <keyword>Canagliflozin (JNJ-28431754)</keyword>
  <keyword>Metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted between 16 May 2013 and 01 December 2014 and recruited participants from 158 study centers in 12 countries worldwide.</recruitment_details>
      <pre_assignment_details>A total of 1,186 participants were randomly allocated to the 5 treatment arms. All participants received at least 1 dose of study drug and were included in the modified intent-to-treat (mITT) analysis set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Metformin XR</title>
          <description>Participants received metformin extended release (XR) tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Canagliflozin 100 Milligram (mg)</title>
          <description>Participants received one 100 milligram (mg) canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Canagliflozin 300 mg</title>
          <description>Participants received one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Canagliflozin 100 mg + Metformin XR</title>
          <description>Participants received one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Canagliflozin 300 mg + Metformin XR</title>
          <description>Participants received one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="237"/>
                <participants group_id="P2" count="237"/>
                <participants group_id="P3" count="238"/>
                <participants group_id="P4" count="237"/>
                <participants group_id="P5" count="237"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="205"/>
                <participants group_id="P2" count="211"/>
                <participants group_id="P3" count="216"/>
                <participants group_id="P4" count="225"/>
                <participants group_id="P5" count="212"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Metformin XR</title>
          <description>Participants received metformin extended release (XR) tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Canagliflozin 100 Milligram (mg)</title>
          <description>Participants received one 100 milligram (mg) canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Canagliflozin 300 mg</title>
          <description>Participants received one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Canagliflozin 100 mg + Metformin XR</title>
          <description>Participants received one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Canagliflozin 300 mg + Metformin XR</title>
          <description>Participants received one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="237"/>
            <count group_id="B2" value="237"/>
            <count group_id="B3" value="238"/>
            <count group_id="B4" value="237"/>
            <count group_id="B5" value="237"/>
            <count group_id="B6" value="1186"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.2" spread="9.75"/>
                    <measurement group_id="B2" value="54.0" spread="10.70"/>
                    <measurement group_id="B3" value="55.8" spread="9.56"/>
                    <measurement group_id="B4" value="54.2" spread="9.58"/>
                    <measurement group_id="B5" value="55.4" spread="9.84"/>
                    <measurement group_id="B6" value="54.9" spread="9.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="121"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="113"/>
                    <measurement group_id="B4" value="129"/>
                    <measurement group_id="B5" value="122"/>
                    <measurement group_id="B6" value="617"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="105"/>
                    <measurement group_id="B3" value="125"/>
                    <measurement group_id="B4" value="108"/>
                    <measurement group_id="B5" value="115"/>
                    <measurement group_id="B6" value="569"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czech Republic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="37"/>
                    <measurement group_id="B6" value="202"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovakia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Africa</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="42"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="54"/>
                    <measurement group_id="B6" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="41"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26</title>
        <description>The change in the value of glycated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) from baseline at Week 26 was compared between the different treatment groups.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>This analysis was conducted using the modified intent-to-treat analysis set, which included all participants who were randomly assigned to a treatment group and received at least 1 dose of study drug. Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Participants received metformin extended release (XR) tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 Milligram (mg)</title>
            <description>Participants received one 100 milligram (mg) canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Canagliflozin 100 mg + Metformin XR</title>
            <description>Participants received one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Canagliflozin 300 mg + Metformin XR</title>
            <description>Participants received one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26</title>
          <description>The change in the value of glycated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) from baseline at Week 26 was compared between the different treatment groups.</description>
          <population>This analysis was conducted using the modified intent-to-treat analysis set, which included all participants who were randomly assigned to a treatment group and received at least 1 dose of study drug. Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable for this outcome measure.</population>
          <units>percentage of hemoglobin</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="230"/>
                <count group_id="O2" value="230"/>
                <count group_id="O3" value="234"/>
                <count group_id="O4" value="235"/>
                <count group_id="O5" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.30" spread="0.071"/>
                    <measurement group_id="O2" value="-1.37" spread="0.071"/>
                    <measurement group_id="O3" value="-1.42" spread="0.070"/>
                    <measurement group_id="O4" value="-1.77" spread="0.069"/>
                    <measurement group_id="O5" value="-1.78" spread="0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.099</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.657</ci_lower_limit>
            <ci_upper_limit>-0.269</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.48</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.099</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.670</ci_lower_limit>
            <ci_upper_limit>-0.280</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.40</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.099</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.594</ci_lower_limit>
            <ci_upper_limit>-0.207</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.36</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.099</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.557</ci_lower_limit>
            <ci_upper_limit>-0.169</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>P value corresponds to a comparison that canagliflozin is noninferior to Metformin XR by a margin of 0.35%.</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.06</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.100</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.258</ci_lower_limit>
            <ci_upper_limit>0.133</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>P value corresponds to a comparison that canagliflozin is noninferior to Metformin XR by a margin of 0.35%.</non_inferiority_desc>
            <p_value>0.001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.11</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.099</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.307</ci_lower_limit>
            <ci_upper_limit>0.082</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Body Weight From Baseline to Week 26</title>
        <description>The percentage change in body weight from baseline to Week 26 was compared between the different treatment groups.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>This analysis was conducted using the modified intent-to-treat analysis set, which included all participants who were randomly assigned to a treatment group and received at least 1 dose of study drug. Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Participants received metformin extended release (XR) tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 Milligram (mg)</title>
            <description>Participants received one 100 milligram (mg) canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Canagliflozin 100 mg + Metformin XR</title>
            <description>Participants received one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Canagliflozin 300 mg + Metformin XR</title>
            <description>Participants received one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Body Weight From Baseline to Week 26</title>
          <description>The percentage change in body weight from baseline to Week 26 was compared between the different treatment groups.</description>
          <population>This analysis was conducted using the modified intent-to-treat analysis set, which included all participants who were randomly assigned to a treatment group and received at least 1 dose of study drug. Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable for this outcome measure.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="237"/>
                <count group_id="O5" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="0.3"/>
                    <measurement group_id="O2" value="-3.0" spread="0.3"/>
                    <measurement group_id="O3" value="-3.9" spread="0.3"/>
                    <measurement group_id="O4" value="-3.5" spread="0.3"/>
                    <measurement group_id="O5" value="-4.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-0.9</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.6</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.8</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.6</ci_lower_limit>
            <ci_upper_limit>-1.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.4</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-2.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.4</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.9</ci_lower_limit>
            <ci_upper_limit>-1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Glycated Hemoglobin (HbAIc) Less Than 7 Percent at Week 26</title>
        <description>The percentage of participants achieved HbAIc less than 7 percent at Week 26 was compared between the different treatment groups.</description>
        <time_frame>Week 26</time_frame>
        <population>This analysis was conducted using the modified intent-to-treat analysis set, which included all participants who were randomly assigned to a treatment group and received at least 1 dose of study drug. Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Participants received metformin extended release (XR) tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 Milligram (mg)</title>
            <description>Participants received one 100 milligram (mg) canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Canagliflozin 100 mg + Metformin XR</title>
            <description>Participants received one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Canagliflozin 300 mg + Metformin XR</title>
            <description>Participants received one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Glycated Hemoglobin (HbAIc) Less Than 7 Percent at Week 26</title>
          <description>The percentage of participants achieved HbAIc less than 7 percent at Week 26 was compared between the different treatment groups.</description>
          <population>This analysis was conducted using the modified intent-to-treat analysis set, which included all participants who were randomly assigned to a treatment group and received at least 1 dose of study drug. Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="206"/>
                <count group_id="O3" value="215"/>
                <count group_id="O4" value="224"/>
                <count group_id="O5" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.0"/>
                    <measurement group_id="O2" value="38.8"/>
                    <measurement group_id="O3" value="42.8"/>
                    <measurement group_id="O4" value="49.6"/>
                    <measurement group_id="O5" value="56.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.027</p_value>
            <method>Generalized Linear Mixed Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>2.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Generalized Linear Mixed Model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.46</ci_lower_limit>
            <ci_upper_limit>3.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Systolic Blood Pressure From Baseline at Week 26</title>
        <description>The change in systolic blood pressure from baseline at Week 26 was compared between the different treatment groups.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>This analysis was conducted using the modified intent-to-treat analysis set, which included all participants who were randomly assigned to a treatment group and received at least 1 dose of study drug. Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Participants received metformin extended release (XR) tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 Milligram (mg)</title>
            <description>Participants received one 100 milligram (mg) canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Canagliflozin 100 mg + Metformin XR</title>
            <description>Participants received one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Canagliflozin 300 mg + Metformin XR</title>
            <description>Participants received one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Systolic Blood Pressure From Baseline at Week 26</title>
          <description>The change in systolic blood pressure from baseline at Week 26 was compared between the different treatment groups.</description>
          <population>This analysis was conducted using the modified intent-to-treat analysis set, which included all participants who were randomly assigned to a treatment group and received at least 1 dose of study drug. Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable for this outcome measure.</population>
          <units>millimeter of mercury (mm Hg)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="236"/>
                <count group_id="O3" value="236"/>
                <count group_id="O4" value="237"/>
                <count group_id="O5" value="236"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.633"/>
                    <measurement group_id="O2" value="-2.24" spread="0.627"/>
                    <measurement group_id="O3" value="-2.36" spread="0.622"/>
                    <measurement group_id="O4" value="-2.24" spread="0.613"/>
                    <measurement group_id="O5" value="-1.65" spread="0.624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.060</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.91</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.882</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.641</ci_lower_limit>
            <ci_upper_limit>-0.182</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.147</p_value>
            <method>Mixed Model for Repeated Measures (MMRM)</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>-1.31</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.889</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.058</ci_lower_limit>
            <ci_upper_limit>0.431</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Fasting High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26</title>
        <description>The percentage change in Fasting High-Density Lipoprotein Cholesterol (HDL-C) from baseline to Week 26 was compared between the different treatment groups.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Participants received metformin extended release (XR) tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 Milligram (mg)</title>
            <description>Participants received one 100 milligram (mg) canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Canagliflozin 100 mg + Metformin XR</title>
            <description>Participants received one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Canagliflozin 300 mg + Metformin XR</title>
            <description>Participants received one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Fasting High-Density Lipoprotein Cholesterol (HDL-C) From Baseline to Week 26</title>
          <description>The percentage change in Fasting High-Density Lipoprotein Cholesterol (HDL-C) from baseline to Week 26 was compared between the different treatment groups.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable for this outcome measure.</population>
          <units>percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="222"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="228"/>
                <count group_id="O4" value="227"/>
                <count group_id="O5" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" spread="1.5"/>
                    <measurement group_id="O2" value="17.6" spread="1.5"/>
                    <measurement group_id="O3" value="16.6" spread="1.5"/>
                    <measurement group_id="O4" value="15.5" spread="1.5"/>
                    <measurement group_id="O5" value="14.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.147</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>5.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.2</ci_lower_limit>
            <ci_upper_limit>9.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.147</p_value>
            <method>ANCOVA</method>
            <param_type>Least-Squares Mean Difference</param_type>
            <param_value>4.3</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.1</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2</ci_lower_limit>
            <ci_upper_limit>8.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Triglycerides From Baseline to Week 26</title>
        <description>The percentage change in triglycerides from baseline to Week 26 was compared between the different treatment groups.</description>
        <time_frame>Day 1 (Baseline) and Week 26</time_frame>
        <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Participants received metformin extended release (XR) tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 Milligram (mg)</title>
            <description>Participants received one 100 milligram (mg) canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Canagliflozin 100 mg + Metformin XR</title>
            <description>Participants received one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Canagliflozin 300 mg + Metformin XR</title>
            <description>Participants received one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Triglycerides From Baseline to Week 26</title>
          <description>The percentage change in triglycerides from baseline to Week 26 was compared between the different treatment groups.</description>
          <population>Analysis used mITT analysis set (all randomized patients who received at least 1 dose of study drug). Here &quot;N&quot; (Number of Participants Analyzed) signifies number of Participants who were evaluable for this outcome measure.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="223"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="229"/>
                <count group_id="O4" value="229"/>
                <count group_id="O5" value="225"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6" spread="51.8"/>
                    <measurement group_id="O2" value="1.7" spread="50.5"/>
                    <measurement group_id="O3" value="2.8" spread="60.3"/>
                    <measurement group_id="O4" value="13.0" spread="81.9"/>
                    <measurement group_id="O5" value="21.2" spread="71.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.608</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hodges-Lehman Estimate</param_type>
            <param_value>-3.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.1</ci_lower_limit>
            <ci_upper_limit>3.4</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.806</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
            <param_type>Hodges-Lehman Estimate</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>10.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment Emergent Adverse Events (AEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.</description>
        <time_frame>Up to 30 weeks of last study drug administration</time_frame>
        <population>Safety Analysis Set included all randomized participants who received at least 1 dose of double-blind study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Metformin XR</title>
            <description>Participants received metformin extended release (XR) tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Canagliflozin 100 Milligram (mg)</title>
            <description>Participants received one 100 milligram (mg) canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Canagliflozin 300 mg</title>
            <description>Participants received one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Canagliflozin 100 mg + Metformin XR</title>
            <description>Participants received one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
          </group>
          <group group_id="O5">
            <title>Canagliflozin 300 mg + Metformin XR</title>
            <description>Participants received one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment Emergent Adverse Events (AEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between administration of study drug and up to 30 days after last dose of study drug that were absent before treatment or that worsened relative to pre-treatment state.</description>
          <population>Safety Analysis Set included all randomized participants who received at least 1 dose of double-blind study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="237"/>
                <count group_id="O3" value="238"/>
                <count group_id="O4" value="237"/>
                <count group_id="O5" value="237"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="95"/>
                    <measurement group_id="O4" value="99"/>
                    <measurement group_id="O5" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 30 weeks of last study drug administration</time_frame>
      <desc>The total number of adverse events listed in the &quot;Other (non-Serious) Adverse Event&quot; table are based on atleast 2 percent of participants experiencing the adverse event in any treatment arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>Metformin XR</title>
          <description>Participants received metformin extended release (XR) tablets (in doses titrated over 9 weeks) once daily with the evening meal, plus one placebo capsule before the morning meal and one placebo capsule with the evening meal (to match the canagliflozin capsules administered in other treatment arms) for 26 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Canagliflozin 100 Milligram (mg)</title>
          <description>Participants received one 100 milligram (mg) canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Canagliflozin 300 mg</title>
          <description>Participants received one 300 mg canagliflozin capsule before the morning meal and one matching placebo capsule with the evening meal plus placebo tablets with the evening meal (to match the metformin XR tablets administered in other treatment arms) for 26 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Canagliflozin 100 mg + Metformin XR</title>
          <description>Participants received one 100 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Canagliflozin 300 mg + Metformin XR</title>
          <description>Participants received one 300 mg canagliflozin capsule with the evening meal and one matching placebo capsule before the morning meal plus metformin XR tablets (in doses titrated over 9 weeks) once daily with the evening meal for 26 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Immune Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Epiploic Appendagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Ophthalmic Herpes Simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Extradural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Post Laminectomy Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Medullary Thyroid Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Cervicobrachial Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA Version 17.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="38" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="237"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Glomerular Filtration Rate Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="237"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="237"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="238"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="237"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="237"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>A copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Director Clinical Research</name_or_title>
      <organization>Janssen Research &amp; Development, LLC</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

